Partner Article

Early Cancer Screening: UK leading health, well-being and diagnostics provider Get A Drip, launches ground-breaking new blood test

Get A Drip, the Letchworth headquartered UK leading provider of health, well-being and diagnostics solutions and technologies, has partnered with TruCheck™ to become one of the UK’s first providers to offer a revolutionary new Early Cancer Screening Blood Test to the British public.

As the most convenient and effective way to detect cancer cells at their earliest stage, the test – which increases the chance of successful treatment - follows the release of the latest Cancer Research UK data revealing some 375,000 new cancer cases are detected in the UK every year while there are over 167,000 cancer related deaths.

The Early Cancer Screening Blood Test identifies 70 cancers, including the top four cancers in the UK – breast, prostate, lung and bowel cancer - which are responsible for more than half of all new cases in the UK – and involves a simple blood test which analyses for Circulating Tumour Cells (CTCs) and cluster cells, to determine your current cancer status. If cancer is detected, it also pinpoints the tumour’s location, allowing for a quicker, more targeted treatment. This helps prevent the spread of cancer to other parts of the body as well as acutely identifying the type of cancer(s).

Now available across Get A Drip’s core London clinics, including Canary Wharf, Westfield White City, Westfield Stratford City and BOXPARK Shoreditch, customers can book an initial free pre-consultation with a TruCheck™ doctor to check their eligibility, before the blood test is promptly administered by one of Get A Drip’s team of registered nurses.

Get A Drip has introduced the testing service following comprehensive clinical trials involving more than 40,000 participants. Meeting specific clinical requirements is necessary to qualify for the test, which is currently only available to those over 40 years old, and the Early Cancer Screening Blood Test has been found to exhibit a sensitivity of 88.24%, representing the test’s ability to detect CTCs within blood samples derived from individuals with cancer. The specificity denoting the absence of false positive CTC detections in blood samples from both healthy individuals and those with benign conditions meanwhile is 99.97%, and the overall ability to determine tissue or organ of origin in positive cases is 96.83%, meaning the test is remarkably accurate.

As an extension of Get A Drip’s already extensive offering of market leading vitamin drips, vitamin injections, diagnostics and wider health and well-being technologies, the addition of the Early Cancer Screening Blood Test further solidifies Get A Drip’s stance as a leading preventative healthcare provider seeking to make solutions more accessible than ever before.

Dr Matthew Calcasola, chief medical officer at Get A Drip and a general medical council doctor, NHS GP partner, and member of the Royal College of General Practitioners explains: “As the only publicly available test to check for Circulating Tumour Cells (CTCs), detecting even the tiniest existence of cancer from a small blood sample, we’re proud to be able to offer it to consumers across our core London clinics.”

He adds: “While it should not replace conventional cancer screening, it is a powerful addition to overall health screening which will speed up diagnosis and treatment, enabling doctors to focus treatment on the required areas.”

Almost half of all cancer cases are currently diagnosed at stage 3 or 4 – but it is hoped that diagnosis of more patients at stage 1 or 2 can have a massive impact on treatment and survival rates.

Get A Drip CEO and co-founder Richard Chambers explains: “Research backs early identification to be key when it comes to treating cancer and increasing chances of remission – through our CQC registered clinics which uphold the highest medical standards, we’re proud to be able to make early detection more accessible to the British public.”

This was posted in Bdaily's Members' News section by Lucie Hayes .